Search research articles
Contact Us
Filters
Showing results (381-390 of 703) with videos related to
Page
of 71
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2021
Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma
Judith M Versluis, Irene L M Reijers, Elisa A Rozeman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma
Caroline Robert, Matteo S Carlino, Catriona McNeil, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 11, 2018
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
Matteo S Carlino, Georgina V Long, Dirk Schadendorf, et al.
Lancet (London, England)
|
August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter, Antoni Ribas, Georgina V Long, et al.
Journal of the American Academy of Dermatology
|
September 7, 2024
Comparison of clinicopathological features and treatment outcomes for cutaneous melanomas of the head and neck and melanomas arising at other sites: Implications for systemic therapy
Andrew T Li, Jessie X Xu, Tyler R Blah, et al.
Plos One
|
November 1, 2023
Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia
Nila J Dharan, Sarah C Sasson, Golo Ahlenstiel, et al.
Lancet (London, England)
|
May 22, 2012
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
Gerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2021
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Georgina V Long, Caroline Robert, Marcus O Butler, et al.
Oncotarget
|
October 22, 2014
TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells
Selina K Sutton, Jessica Koach, Owen Tan, et al.
Pigment Cell & Melanoma Research
|
October 7, 2019
Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma
Robert Mason, Helen C Dearden, Bella Nguyen, et al.
Page
of 71
Search research articles
Search
Showing results (381-390 of 703) with videos related to
Sort By:
Page
of 71
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2021
Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma
Judith M Versluis, Irene L M Reijers, Elisa A Rozeman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma
Caroline Robert, Matteo S Carlino, Catriona McNeil, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 11, 2018
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
Matteo S Carlino, Georgina V Long, Dirk Schadendorf, et al.
Lancet (London, England)
|
August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter, Antoni Ribas, Georgina V Long, et al.
Journal of the American Academy of Dermatology
|
September 7, 2024
Comparison of clinicopathological features and treatment outcomes for cutaneous melanomas of the head and neck and melanomas arising at other sites: Implications for systemic therapy
Andrew T Li, Jessie X Xu, Tyler R Blah, et al.
Plos One
|
November 1, 2023
Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia
Nila J Dharan, Sarah C Sasson, Golo Ahlenstiel, et al.
Lancet (London, England)
|
May 22, 2012
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
Gerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2021
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Georgina V Long, Caroline Robert, Marcus O Butler, et al.
Oncotarget
|
October 22, 2014
TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells
Selina K Sutton, Jessica Koach, Owen Tan, et al.
Pigment Cell & Melanoma Research
|
October 7, 2019
Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma
Robert Mason, Helen C Dearden, Bella Nguyen, et al.
Page
of 71